Article
A syngeneic glioblastoma mouse model with mesenchymal hallmarks.
Neuroscience - 16 Apr 2026
Joseph Justin V, Blaavand Mathilde S, Kelstrup Gustav W, Rasmussen Sofie A, Cai Huiqiang, Vendelbo Mikkel, Thomsen Martin K
Abstract excerpt
Primary brain cancer has a poor prognosis, and especially glioblastoma (GBM) patients have a median survival of only 15 months. The standard of care treatment has not changed in the last 20 years, highlighting the need for research and development, which would warrant the need for better model systems. Mouse models of GBM allow researchers to address biological questions in a physiological setting that resembles...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
